Octapharma Pharmazeutika Produktionsgesellschaft mbH

5 trials 1 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

3 Completed trials

14 Countries active

3 Unique IMPs

100% Results reported

Phase III

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Infection prophylaxis 1 Primary immunodeficiency syndrome 1

Top IMPs

HUMAN NORMAL IMMUNOGLOBULIN 4 SODIUM CHLORIDE 3 C1 ESTERASE INHIBITOR (HUMAN) 1

All trials

5 total

Supporting weak immune system during autoimmune therapy: testing Panzyga to prevent infections Pending

2025-522854-37-00 Phase III 8 countries HUMAN NORMAL IMMUNOGLOBULIN; SODIUM CHLORIDE
Prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety phase 3 study of an intravenous … Recruiting

2023-503507-29-00 Phase III 2 countries C1 ESTERASE INHIBITOR (HUMAN); SODIUM CHLORIDE
A superiority study to compare the effect of Panzyga versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome Ended

2024-511673-30-00 Phase III 2 countries HUMAN NORMAL IMMUNOGLOBULIN
Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcu… Ended

2024-511231-94-00 Phase III 5 countries HUMAN NORMAL IMMUNOGLOBULIN
Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective pha… Ended

2023-509737-39-00 Phase III 7 countries HUMAN NORMAL IMMUNOGLOBULIN; SODIUM CHLORIDE

Showing 1–5 of 5 trials

← All sponsors A–Z